Neuronal nicotinic acetylcholine receptor (nAChR) alpha-4 beta-2 and alpha-6 beta-2 subtypes (nAChR)

Neuronal nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels that mediate fast synaptic transmission and modulate the release of various neurotransmitters (nih.gov, 1.1.3). The α4β2 and α6β2 subtypes are particularly significant in the central nervous system; α4β2 is the most widely expressed high-affinity nicotine-binding subtype, while α6β2 is localized primarily in catecholaminergic nuclei like the substantia nigra and ventral tegmental area (nih.gov, 1.3.1). These receptors are central to the rewarding effects of nicotine and are key targets for smoking cessation therapies like varenicline (patsnap.com, 1.3.3). Beyond addiction, they play vital roles in cognitive functions such as attention and memory, making them therapeutic targets for Alzheimer's and Parkinson's diseases (nih.gov, 1.3.2). Drugs interacting with these receptors can act as full or partial agonists to stimulate neurotransmitter release or as antagonists to block the effects of exogenous nicotine (wikipedia.org, 1.3.4). Given their diverse roles, achieving subtype selectivity is a major focus in drug development to minimize off-target effects and improve safety profiles (acs.org, 1.1.1).

Other names

alpha-4 beta-2 nicotinic acetylcholine receptoralpha-6 beta-2 nicotinic acetylcholine receptornAChR alpha4beta2nAChR alpha6beta2CHRNA4/CHRNB2 receptorCHRNA6/CHRNB2 receptorNicotinic acetylcholine receptor alpha-4 beta-2Nicotinic acetylcholine receptor alpha-6 beta-2

Drugs targeting these receptors act as agonists, partial agonists, or antagonists at the orthosteric ligand-binding site, or as allosteric modulators, to regulate the opening of the cation-selective pore, thereby influencing membrane potential and the release of neurotransmitters such as dopamine and glutamate (nih.gov, 1.3.3).